Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexamethasone cipecilate dry powder

Drug Profile

Dexamethasone cipecilate dry powder

Alternative Names: Erizas; NS-126; NS-126C

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hisamitsu Pharmaceutical
  • Developer Nippon Shinyaku; Yooyoung Pharmaceutical
  • Class Antiallergics; Antiasthmatics; Glucocorticoids; Pregnadienetriols
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinitis
  • Discontinued Asthma

Most Recent Events

  • 01 Feb 2016 Launched for Allergic rhinitis in South Korea (Intranasal)
  • 03 Dec 2015 Preregistration for Allergic rhinitis in South Korea (Intranasal) prior to December 2015 (Yooyoung Pharmaceutical's pipeline, December 2015)
  • 06 Mar 2014 Discontinued - Phase-II for Asthma in Japan (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top